Top Qs
Timeline
Chat
Perspective
Aleniglipron
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics.[1] It is delivered orally and is in a Phase II trial as of 2023.[2][3][4] In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.[5]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads